Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Electron microscopy of T cells on a fluid lipid bilayer, supported by mesoporous silica micro-rods (pseudocolored). Cheung et al. show that this scaffold can be used to mimic antigen presentation to T cells, improving the outcome of T-cell expansion for adoptive cellular therapies (p 160). Image credit: Alexander Cheung, Sandeep Koshy and David Zhang.
A positive regulatory environment, combined with a raft of drug approvals that included the first US gene therapy, buoyed the sector in 2017. The FDA's flexibility and focus on marketplace competition is likely to galvanize innovators in the coming year. Chris Morrison reports.
Drug–device combination products are becoming increasingly prevalent, with many lasting years beyond the expiration date of primary and secondary patents on the drug itself.
Combining gene activation and knockout of different genes in the same cell using two different Cas9 enzymes enables the reconstruction of directional dependency.